2011 Scrip 100: Dragons, tigers and kangaroos
This article was originally published in Scrip
Diverse, developed and developing, the Asian pharmaceutical markets have an appetite for both innovative products and branded generics. Bayer Schering Pharma's strategy for growth in the region includes investment in both, Alok Kanti tells Ian Haydock.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.